Terodiline

Summary

Terodiline (CHEMBL363295) is an approved small molecule (ATC G04BD05); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BD05
• Indications: 2 conditions
• Chemistry: 281.4 Da · C20H27N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL363295
Name	Terodiline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23480
ATC	G04BD05
Molecular formula	C20H27N
Molecular weight	281.4
InChIKey	UISARWKNNNHPGI-UHFFFAOYSA-N

SMILES: CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C

IUPAC name: N-tert-butyl-4,4-diphenylbutan-2-amine

Also known as: Terodilina, Terodiline, terodiline, TERODILINE

Parent form; salt/anhydrous children: CHEMBL539770

Patent coverage: 1,402 distinct patent families (5,064 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, Voltage-gated L-type calcium channel, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor, Histamine H1 receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	6.3	IC50	500	nM	CHEMBL_ACT_1449630
KCNH2	6.21	AC50	620	nM	CHEMBL_ACT_25117798
HRH1	6.12	AC50	760	nM	CHEMBL_ACT_25212462
CHRM3	5.96	AC50	1100	nM	CHEMBL_ACT_25136640
CHRM1	5.85	AC50	1400	nM	CHEMBL_ACT_25135403
CHRM2	5.51	AC50	3100	nM	CHEMBL_ACT_25213692
CACNA1F	5.32	IC50	4800	nM	CHEMBL_ACT_15373364
KCNH2	5.24	IC50	5754	nM	CHEMBL_ACT_5218917
OPRK1	5.08	AC50	8400	nM	CHEMBL_ACT_25129381
SCN5A	5.06	AC50	8649	nM	CHEMBL_ACT_25158908

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).